Shots:

• On Feb 12- 2021- the US FDA has approved Cosela to decrease the incidence of CT induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC
• The launch is supported by the “One Patient Support Program” which is designed to provide access and affordability solutions to eligible patients
• Cosela is the 1st therapy designed to help protect bone marrow (myeloprotection) when administered before treatment with CT

 ­ Ref: GlobeNewswire  | Image: BioSpace